Axsome Therapeutics Inc. $(AXSM)$, a biopharmaceutical company specializing in central nervous system disorders, announced that data from the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the upcoming 67th Annual Scientific Meeting of the American Headache Society (AHS). The event is scheduled to take place from June 19-22, 2025, in Minneapolis, Minnesota. The presentation will include results from multiple trials, including the INTERCEPT, EMERGE, and MOVEMENT trials, focusing on the efficacy, safety, and long-term effects of SYMBRAVO® in migraine treatment. Key presentations are scheduled for June 19 and June 21, 2025, featuring prominent researchers such as Dr. Richard B. Lipton and Dr. Stewart Tepper.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.